Jade Biosciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Jade Biosciences, Inc. (JBIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $19.70 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2025-03-27
- Jade Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $19.75, a 21.03% decline year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $25.01, a 99.12% increase year-over-year.
- Jade Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $12.56.
- Jade Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $19.70, a 13.79% decline from fiscal 2023.
- Jade Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $22.85, a 46.29% increase from fiscal 2022.
- Jade Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $15.62, a 116.64% increase from fiscal 2021.
- Jade Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $7.21.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $19.70 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $19.70 10-Q · filed 2024-11-12 | |||
| 2024-06-30 | $19.70 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $19.75 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $22.85 10-K · filed 2024-03-25 | |||
| 2023-09-30 | $23.48 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $24.01 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $25.01 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $15.62 10-K · filed 2023-03-29 | |||
| 2022-09-30 | $15.03 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $13.08 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $12.56 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $7.21 10-K · filed 2022-03-30 | |||
| 2021-09-30 | $6.15 10-Q · filed 2021-11-15 | |||
| 2021-06-30 | $6.04 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |